NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Researchers at NIH have discovered key intracellular signaling processes involved in the weight-loss effects of semaglutide, a GLP-1 drug. The findings may help extend treatment duration and reduce plateaus experienced by patients.